Matches in SemOpenAlex for { <https://semopenalex.org/work/W69891408> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W69891408 endingPage "7" @default.
- W69891408 startingPage "433" @default.
- W69891408 abstract "Combined treatment of fludarabine (FLU) with cyclophosphamide (CY) may increase the complete remission (CR) rate, decreased minimal residual disease (MRD) and, possibly, prolong survival in B-chronic lymphocytic leukemia patient's (B-CLL). The aim of study was to evaluate the activity and toxicity of FLU in combination with CY, the FLU-CY schedule, in patients with previously untreated B-CLL. From May 1999 to December 2002, 57 patients with advanced or progressive B-CLL received treatment with FLU at a dose of 30 mg/m2 for three consecutive days and CY at a dose of 300 mg/m2 for three days. The cycles were repeated at four week intervals or longer if severe myelosupression occurred. Guidelines for the evalution of response and toxicity were those developed by the National Cancer Institute Sponsored Working Group. Minimal residual disease (MRD) was detected by immunophenotyping only in patients with CR by standard criteria. In the analyzed group an overall response (OR) rate (CR+PR) of 89.5% (95% CI 80.6-94.7%) was achieved, including complete response in 29.8%. At the time of analysis 15 of 17 patients with CR are still in remission. Median duration of follow up in these is 12 (range 4-29.2) months. MRD was detected only in five out of 17(29.4%) patients with CR. Grade III/IV thrombocytopenia was seen in 3 (5.2%) patients and grade III/IV neutropenia in 6 (10.5%). Severe infections were noted in 14 (24%) patients. Two (3.5%) patients died, one due to sepsis, one as a result of disease progression. The FLU-CY regimen is highly effective combination in previously untreated CLL patients with acceptable toxicity. The efficacy of the regimen seems to be higher than that observed earlier after treatment with FLU alone." @default.
- W69891408 created "2016-06-24" @default.
- W69891408 creator A5000747228 @default.
- W69891408 creator A5003395249 @default.
- W69891408 creator A5026473561 @default.
- W69891408 creator A5042592001 @default.
- W69891408 creator A5078478829 @default.
- W69891408 date "2003-01-01" @default.
- W69891408 modified "2023-09-23" @default.
- W69891408 title "Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia." @default.
- W69891408 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14689065" @default.
- W69891408 hasPublicationYear "2003" @default.
- W69891408 type Work @default.
- W69891408 sameAs 69891408 @default.
- W69891408 citedByCount "2" @default.
- W69891408 countsByYear W698914082022 @default.
- W69891408 crossrefType "journal-article" @default.
- W69891408 hasAuthorship W69891408A5000747228 @default.
- W69891408 hasAuthorship W69891408A5003395249 @default.
- W69891408 hasAuthorship W69891408A5026473561 @default.
- W69891408 hasAuthorship W69891408A5042592001 @default.
- W69891408 hasAuthorship W69891408A5078478829 @default.
- W69891408 hasConcept C126322002 @default.
- W69891408 hasConcept C141071460 @default.
- W69891408 hasConcept C2776694085 @default.
- W69891408 hasConcept C2776755627 @default.
- W69891408 hasConcept C2777063308 @default.
- W69891408 hasConcept C2777938653 @default.
- W69891408 hasConcept C2778461978 @default.
- W69891408 hasConcept C2779263901 @default.
- W69891408 hasConcept C2779338263 @default.
- W69891408 hasConcept C2779823535 @default.
- W69891408 hasConcept C2780653079 @default.
- W69891408 hasConcept C29730261 @default.
- W69891408 hasConcept C71924100 @default.
- W69891408 hasConcept C90924648 @default.
- W69891408 hasConceptScore W69891408C126322002 @default.
- W69891408 hasConceptScore W69891408C141071460 @default.
- W69891408 hasConceptScore W69891408C2776694085 @default.
- W69891408 hasConceptScore W69891408C2776755627 @default.
- W69891408 hasConceptScore W69891408C2777063308 @default.
- W69891408 hasConceptScore W69891408C2777938653 @default.
- W69891408 hasConceptScore W69891408C2778461978 @default.
- W69891408 hasConceptScore W69891408C2779263901 @default.
- W69891408 hasConceptScore W69891408C2779338263 @default.
- W69891408 hasConceptScore W69891408C2779823535 @default.
- W69891408 hasConceptScore W69891408C2780653079 @default.
- W69891408 hasConceptScore W69891408C29730261 @default.
- W69891408 hasConceptScore W69891408C71924100 @default.
- W69891408 hasConceptScore W69891408C90924648 @default.
- W69891408 hasIssue "6" @default.
- W69891408 hasLocation W698914081 @default.
- W69891408 hasOpenAccess W69891408 @default.
- W69891408 hasPrimaryLocation W698914081 @default.
- W69891408 hasRelatedWork W1925009128 @default.
- W69891408 hasRelatedWork W2362661449 @default.
- W69891408 hasRelatedWork W2533912613 @default.
- W69891408 hasRelatedWork W2548712183 @default.
- W69891408 hasRelatedWork W2556997696 @default.
- W69891408 hasRelatedWork W2564158403 @default.
- W69891408 hasRelatedWork W2979934701 @default.
- W69891408 hasRelatedWork W2980214149 @default.
- W69891408 hasRelatedWork W4234074256 @default.
- W69891408 hasRelatedWork W69891408 @default.
- W69891408 hasVolume "50" @default.
- W69891408 isParatext "false" @default.
- W69891408 isRetracted "false" @default.
- W69891408 magId "69891408" @default.
- W69891408 workType "article" @default.